Medicines and Healthcare Products Regulatory Agency issued a conditional authorization Thursday for molnupiravir, the drug developed by Merck and Ridgeback Biotherapeutics.
Through the 29th day of treatment, about 7% of patients who received the drug were hospitalized or died due to COVID-19, compared with 14% of patients who received a placebo, the release said.
Last week, Merck announced it had signed a voluntary licensing agreement with the Medicines Patent Pool, a U.N.-backed public health organization, to let other drugmakers produce its pill.
Rhonda Achonolu comforts her son Amechi, 7, as he is inoculated with first dose of the Pfizer-BioNTech COVID-19 vaccine for children 5 to 11 years old at The Children’s Hospital at Montefiore, Wednesday, Nov.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.